| Literature DB >> 31266194 |
Subin Kim1, Myeong Ju Moon2, Suchithra Poilil Surendran1, Yong Yeon Jeong3.
Abstract
Hyaluronic acid (HA) is a non-sulfated polysaccharide polymer with the properties of biodegradability, biocompatibility, and non-toxicity. Additionally, HA specifically binds to certain receptors that are over-expressed in cancer cells. To maximize the effect of drug delivery and cancer treatment, diverse types of nanomaterials have been developed. HA-based nanomaterials, including micelles, polymersomes, hydrogels, and nanoparticles, play a critical role in efficient drug delivery and cancer treatment. Hyperthermic cancer treatment using HA-based nanomaterials has attracted attention as an efficient cancer treatment approach. In this paper, the biomedical applications of HA-based nanomaterials in hyperthermic cancer treatment and combined therapies are summarized. HA-based nanomaterials may become a representative platform in hyperthermic cancer treatment.Entities:
Keywords: cancer; combined cancer treatment; hyaluronic acid (HA); hyperthermia; magnetic hyperthermia therapy (MHT); nanomaterials; photothermal therapy (PTT)
Year: 2019 PMID: 31266194 PMCID: PMC6680516 DOI: 10.3390/pharmaceutics11070306
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schemes of nanoparticle (NP)-mediated hyperthermia. (a) Photothermal therapy (PTT) by near-infrared (NIR) laser irradiation to the tumor region, and (b) magnetic hyperthermia therapy (MHT) by alternating magnetic field (AMF) application.
Nanomaterials for hyperthermic cancer treatment.
| NIR-Responsive Materials | Molecular Weight of HA | Core | Composition | Cell Line | Status | Ref. |
|---|---|---|---|---|---|---|
| NIR-dye | 0.48 MDa | IR780-iodide | HA-IR780 | TC-1 | In vivo | [ |
| 50 kDa | IR808 | HAIR | A549 (human lung carcinoma) | In vivo | [ | |
| 32 kDa | IR825 | PFOB@IR825-HA-Cy5.5 | HT-29 | In vivo | [ | |
| Gold NPs | 31.2 kDa | Fe3O4@Ag | Fe3O4@Au-HA NSs | HeLa (human cervical cancer) | In vivo | [ |
| Graphene oxide NPs | 100 kDa | Nano GO | NGO-HA | B16F10 (mouse melanoma cancer) | In vivo | [ |
| 9.27 kDa | Reduced GO | HA-rGO | MCF-7, NHDF (normal human dermal fibroblast) | In vitro | [ | |
| Prussian blue NPs | 5805 Da | Fe3O4 | Fe3O4@PB@PEI@BQDs-HA | HeLa | In vivo | [ |
Figure 2Schemes of hyaluronic acid (HA)-based and photothermal nanomaterials for hyperthermic cancer treatment.
Figure 3Aspects of combined photothermal chemotherapy cancer treatment.
HA-modified nanoplatforms for photothermal chemotherapy.
| NIR-Responsive Materials | Molecular Weight of HA | Chemotherapeutic Drugs | Cell Line | Status | Ref. |
|---|---|---|---|---|---|
| ICG | 10 KDa | DOX | HCT-116 | In vivo | [ |
| Gold nanorods | 8000 Da | DOX | MCF-7 | In vivo | [ |
| 190,000 | DOX | SKOV-3 (human ovarian cancer), HOSEpiC (human ovarian surface epithelial cell) | In vitro | [ | |
| 5000 Da | DOX | MCF-7, MCF-7 ADR (drug-resistant human breast adenocarcinoma) | In vitro | [ | |
| Polypyrrole | 200 kDa | Docetaxel (DTX) | 4T1 (mouse breast cancer) | In vivo | [ |
| PB NPs | 32 k | 10-hydroxycamptothecin | HeLa | In vivo | [ |
| Graphene oxide | 10,000 | DOX | SKOV-3 (human ovarian cancer) | In vitro | [ |
| 7000 kDa | DOX | A549 | In vivo | [ |
HA-modified nanoplatforms for combined photothermal photodynamic therapy (PDT).
| NIR-Responsive Materials | Molecular Weight of HA | PDT Agents | Cell Line | Status | Ref. |
|---|---|---|---|---|---|
| Fe3O4 | 5.8 kDa | Pheophorbide-a (PheoA) | K1735 (murine melanoma), NIH3T3 (mouse embryonic fibroblast cell) | In vivo | [ |
| IR-780 iodide | 3 kDa | Polypyrrole | SCC7 (mouse head and neck squamous carcinoma), MDA-MB-231 (human breast cancer) | In vivo | [ |
| Gold nanorods (GNRs) | 8000 Da | 5-aminolevulinic acid (ALA) | MCF-7 | In vivo | [ |
| Carbon nanotubes (CNTs) | 14,000-20,000 | Hematoporphyrin monomethyl ether (HMME) | B16F10 | In vivo | [ |